Use of 99mTc-sestamibi SPECT/CT imaging in predicting the degree of pathological hyperplasia of the parathyroid gland: semi-quantitative analysis
- PMID: 34603992
- PMCID: PMC8408780
- DOI: 10.21037/qims-21-66
Use of 99mTc-sestamibi SPECT/CT imaging in predicting the degree of pathological hyperplasia of the parathyroid gland: semi-quantitative analysis
Abstract
Background: Previous studies have demonstrated that 99mTc-sestamibi (99mTc-MIBI) Single-Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT) imaging is an effective isotopic technique for locating the parathyroid in secondary hyperparathyroidism (SHPT). This study aimed to explore further the correlation between 99mTc-MIBI SPECT/CT imaging and SHPT to demonstrate the value of 99mTc-MIBI SPECT/CT in evaluating the degree of pathological hyperplasia of the parathyroid gland (PG).
Methods: The demographics, surgical records, and follow-up information of 91 patients were recorded and analyzed. A total of 216 paraffin-embedded PGs of 54 patients were obtained and analyzed.
Results: Patients with 99mTc-MIBI negative PG(s) had significantly lower preoperative serum phosphorus and higher serum calcium levels at 6 months postoperatively compared to those with 99mTc-MIBI positive PG(s) (P<0.05). We also found a higher total uptake ratio of the region of interest (URRI) and higher URRI max in the hypocalcemia group than in the non-hypocalcemia group. Both URRI total (P=0.003) and URRI max (P=0.028) were independent risk factors for hypocalcemia 6 months postoperatively. The URRI values of the PGs were significantly positively correlated with glandular weight (R2=0.343, P<0.001), glandular volume (R2=0.240, P<0.001), and degree of pathological hyperplasia (P<0.001). However, the URRI value of the PGs exhibited a notably weak correlation with proliferating cell nuclear antigen (PCNA) (R2=0.035, P=0.006). The area under the receiver operating characteristic curve showed a URRI evaluative value of 0.771 for diffuse and nodular types in 216 PGs (P<0.001). We further evaluated 167 nodular-type PGs, distinguishing between nodular hyperplasia and a single nodule; the URRI evaluative value reached 0.819, which was higher than the volume or weight (P<0.001).
Conclusions: The 99mTc-MIBI SPECT/CT scintigraphy results were related to serum calcium levels at 6 months after total parathyroidectomy with autotransplantation (TPTX+AT), suggesting the occurrence of hypocalcemia (6 months after TPTX+AT). More importantly, this technique effectively evaluated the pathological hyperplasia of PGs preoperatively, and therefore, could assist surgeons in selecting the PGs with the lowest degree of hyperplasia intraoperatively.
Keywords: 99mTc-MIBI; hyperplasia; hypocalcemia; parathyroid gland; secondary hyperparathyroidism.
2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All the authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/qims-21-66). The authors have no conflicts of interest to declare.
Figures





Similar articles
-
Comparison of biochemical markers and technetium 99m methoxyisobutylisonitrile imaging in primary and secondary hyperparathyroidism.Front Endocrinol (Lausanne). 2023 Mar 27;14:1094689. doi: 10.3389/fendo.2023.1094689. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37051197 Free PMC article.
-
Diagnostic performance of ultrasonography, dual-phase 99mTc-MIBI scintigraphy, early and delayed 99mTc-MIBI SPECT/CT in preoperative parathyroid gland localization in secondary hyperparathyroidism.BMC Med Imaging. 2020 Aug 3;20(1):91. doi: 10.1186/s12880-020-00490-3. BMC Med Imaging. 2020. PMID: 32746794 Free PMC article.
-
18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients.Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1762-1771. doi: 10.1007/s00259-018-3980-9. Epub 2018 Mar 8. Eur J Nucl Med Mol Imaging. 2018. PMID: 29516131 Free PMC article. Clinical Trial.
-
Detection rate of (99m) Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: A meta-analysis.Head Neck. 2016 Apr;38 Suppl 1:E2159-72. doi: 10.1002/hed.24027. Epub 2015 Jul 6. Head Neck. 2016. PMID: 25757222 Review.
-
Surgical Management of Secondary Hyperparathyroidism.Kidney Int Rep. 2020 Dec 30;6(2):254-264. doi: 10.1016/j.ekir.2020.11.023. eCollection 2021 Feb. Kidney Int Rep. 2020. PMID: 33615051 Free PMC article. Review.
Cited by
-
Comparison of biochemical markers and technetium 99m methoxyisobutylisonitrile imaging in primary and secondary hyperparathyroidism.Front Endocrinol (Lausanne). 2023 Mar 27;14:1094689. doi: 10.3389/fendo.2023.1094689. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37051197 Free PMC article.
-
99mTc-methoxyisobutylisonitrile single-photon emission computed tomography/computed tomography parathyroid imaging in the diagnosis of functional parathyroid cysts: an initial experience.Gland Surg. 2024 Jan 29;13(1):32-44. doi: 10.21037/gs-23-273. Epub 2024 Jan 25. Gland Surg. 2024. PMID: 38323231 Free PMC article.
-
Quantitative application of dual-phase 99mTc-sestamibi SPECT/CT imaging of parathyroid lesions: identification of optimal timing in secondary hyperparathyroidism.EJNMMI Phys. 2023 Apr 20;10(1):29. doi: 10.1186/s40658-023-00548-5. EJNMMI Phys. 2023. PMID: 37079194 Free PMC article.
References
-
- Zawierucha J, Malyszko J, Malyszko JS, Prystacki T, Marcinkowski WP, Dryl-Rydzynska T. Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study-A Comparison. Front Endocrinol (Lausanne) 2019;10:40. 10.3389/fendo.2019.00040 - DOI - PMC - PubMed
-
- Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD, Silver J, Spiegel DM, Sterling L, Walsh L, Chertow GM. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA 2017;317:146-55. 10.1001/jama.2016.19456 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous